![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 21, 2024 6:24:56 PM
There are several advantages for FDA approval and no disadvantages. Also, like some pharmaceutical drugs. All are not approved for insurance reimbursement. But that would be a great advantage in selling and buying the ring if Medicare and insurance companies added the ring to the list of covered products.
I don’t see that happening anytime soon. Not unless the organization AARP and prominent people puts pressure on insurance companies.
That too will not happen anytime soon.
Now specifically getting back to your question.
What you are really asking is the use of LQMT’s Liquidmetal trademark and formula a violation to any part of the Apple/LQMT agreements?
There are no grey areas there. So let’s play devils advocate. Let’s say the answer is 1000% yes!
Then Apple has 9 months in which to file a lawsuit. Otherwise it will become very difficult to fight the law of precedence, since none of the parties involved are hiding anything. It’s public knowledge to the extent of each party knowing what the other is doing.
It’s not a question of whether large sums of $$$$ or frivolous sums of $$$$ are at stake. It is a question of in your mind according to what you know. Is LQMT violating an agreement or not.
After November 2024 you will have your answer. No lawsuit and you can conclude either LQMT was granted a waiver per the agreement or there is no violation. To presume that there was a violation of the CE agreement and Apple did not want to pursue a lawsuit definitively would not be in Apple’s shareholders interest as it would be cause for encouraging more violations and loss of perceived revenues.
In the latter case, the shareholders could then sue Apple. Not a place to be as a ceo of a mega cap.
Now either way a company can call this type of product a medical device without FDA approval.
They just have to add a disclaimer. That’s all.
Good luck to you.
Recent LQMT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:14:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:11:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:49:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 10:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 10:26:27 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM